V8 Peptides — Engineered Performance
Research Library
TB-500 Muscle and Ligament Animal Studies: Endpoints
TB-500Preclinical

TB-500 Muscle and Ligament Animal Studies: Endpoints

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

The muscle and ligament studies cited for TB-500 used thymosin β4 protein, not the fragment. A rat ligament study reported better histology, larger collagen fibrils and higher mechanical properties at 4 weeks with local delivery; a mdx mouse study reported more regenerating fibers but no significant change in grip strength, cardiac function or fibrosis. Read each endpoint by class, route and time point. Supplied for laboratory research use only.

Searches for TB-500 in muscle and tendon animal models return a lot of confident summaries and very few primary papers. The primary literature that does exist is almost entirely about thymosin β4, the protein from which TB-500 is derived, and it uses a small set of endpoints that are worth understanding on their own terms. This article is about those endpoints: what a ligament biomechanics test measures, what a collagen fibril diameter says, what grip strength and echocardiography can and cannot show in a dystrophic mouse, and how a reader should weigh a result in which some endpoints move and others do not. It is written for laboratory researchers who work with, or plan to work with, the TB-500 research peptide, supplied for laboratory research use only. It makes no claim about use in people or animals. Peptide handling basics are in how to reconstitute a lyophilized peptide.

For the compound background see the TB-500 research overview; for the wider wound-healing literature see TB-500 and thymosin β4 wound-healing animal studies. This guide focuses on musculoskeletal readouts.

First, which molecule was in the animals?

The product page lists TB-500 as the thymosin β4 fragment (17–23), Ac-LKKTETQ, and describes thymosin β4 as a small, highly conserved, actin-sequestering protein. The doping-control literature identifies the key ingredient of a veterinary preparation called TB-500 as a synthetic, N-acetylated version of the 17–23 segment, LKKTETQ, and notes that this segment is described as the region responsible for actin binding, cell migration and wound healing (Ho and colleagues, 2012). The musculoskeletal studies discussed below used the full-length protein. No result in them is a result for the fragment. Everything in this article should be read with that qualifier attached.

Case 1: ligament transection in the rat

A 2013 study asked whether thymosin β4 would improve ligament repair after injury. The medial collateral ligament was sharply transected on the day of surgery, and the exposure group received 100 µL of fibrin sealant containing 1 µg of the protein in the ligament gap. Tissue was evaluated at 4 weeks by hematoxylin and eosin staining, transmission electron microscopy and biomechanical testing. Exposed tissue showed uniform, evenly spaced fiber bundles, whereas collagen fibers in control rats were not evenly spaced; collagen fibril diameters within granulation tissue were significantly larger; and the mechanical properties of the healing tissue and of the femur–ligament–tibia complex were significantly higher than in controls (Xu and colleagues, 2013).

EndpointWhat it measuresWhat a change showsWhat it does not show
H&E histologyOverall tissue organization, cellularity, fiber alignmentWhether healing tissue is more orderly at one time pointFunction, or whether the order persists beyond 4 weeks
Transmission electron microscopy, fibril diameterCollagen fibril size in the repair tissueA structural feature associated with maturing collagenThat bigger fibrils are mechanically better on their own
Biomechanical test of the femur–ligament–tibia complexLoad and stiffness properties of the repaired joint structureThat the repaired structure was mechanically stronger than controls at 4 weeksLong-term durability, or behaviour under physiological loading cycles

Two design features matter more than the headline. First, delivery was local and in a carrier, at the lesion. A result obtained by placing a protein in a fibrin sealant in a surgical gap cannot be read as a result for systemic exposure, and the reverse also holds. Second, the study has a single time point. A 4-week snapshot says nothing about whether the difference closes, widens or reverses at 8 or 12 weeks, and the abstract does not claim otherwise. The abstract's own conclusion is limited to the model: local administration promoted healing of the ligament, histologically and mechanically, in a rat model.

Case 2: chronic administration in dystrophin-deficient mice

A different question was asked in a 2010 study: what happens to skeletal and cardiac muscle in mdx mice, a model of Duchenne muscular dystrophy, after chronic exposure? Female wild-type and mdx mice aged 8–10 weeks received 150 µg of thymosin β4 twice a week for 6 months, and exercise for 30 minutes twice a week was added to promote muscle pathology. Skeletal and cardiac function were assessed with grip strength and high-frequency echocardiography; localization of the protein and fibrosis were assessed by immunohistochemistry and Gomori's trichrome staining. The result was split. Exposed mdx mice showed a significant increase in regenerating skeletal muscle fibers compared with untreated mdx mice, and the protein stained exclusively in regenerating fibers. Grip strength, systolic cardiac function (percent shortening fraction) and skeletal and cardiac fibrosis showed no significant improvement in exposed mdx mice (Spurney and colleagues, 2010).

EndpointTypeResult in exposed mdx mice (per abstract)
Regenerating skeletal muscle fibersHistologySignificantly increased
Grip strengthFunctional, whole animalNo significant improvement
Percent shortening fractionEchocardiography, cardiac functionNo significant difference
Skeletal and cardiac fibrosisHistology (trichrome)No significant improvement

This is a good example of why endpoint class matters. A histological count of regenerating fibers is a statement about tissue activity. Grip strength and shortening fraction are statements about function. A finding that the first moved and the others did not is a legitimate, publishable result, and the abstract reports it in that way. It also illustrates the point about exposure design: 6 months of twice-weekly administration is a very different experiment from a single local application at a surgical site.

Case 3: the wound model, for contrast

The oldest of the three papers used a rat full-thickness skin wound. Thymosin β4 added topically or intraperitoneally increased re-epithelialization by 42% over saline controls at 4 days and by as much as 61% at 7 days, and wounds contracted at least 11% more than controls by day 7, with increased collagen deposition and angiogenesis; keratinocyte migration was stimulated 2–3-fold in a Boyden chamber assay when as little as 10 pg was added (Malinda and colleagues, 1999). Skin is not muscle or tendon. It heals by re-epithelialization and contraction, readouts that have no direct counterpart in a ligament, so these figures should not be carried across to musculoskeletal tissue.

Reading musculoskeletal animal studies: a short checklist

  1. Which molecule? Protein, fragment or a blend. Mixed-molecule claims fail this test first.
  2. Which route and where? Local at the lesion, topical, intraperitoneal and chronic repeated administration answer different questions.
  3. Which time point? One time point cannot show a trajectory.
  4. Which endpoint class? Structure, histology, mechanics and whole-animal function are not interchangeable.
  5. Which comparator? Untreated, vehicle, or carrier-only controls; a fibrin sealant without the protein is the correct control for the ligament design.
  6. How many animals, and which sex? The mdx study used female mice only, which limits what can be said about males.
  7. Were null endpoints reported? A paper that reports what did not move is easier to trust.

What this means for a laboratory planning an experiment with TB-500

If the question is whether the fragment reproduces any of these effects, the studies above supply the readouts but not the answer, because nobody in them tested the fragment. A defensible plan would pair a cell-level assay with a defined control set before any animal work, in a facility with the necessary ethical approvals, and would pre-specify the endpoints. Useful controls are a vehicle, a carrier-only arm where a carrier is used, and a scrambled or reversed-sequence peptide carrying the same N-terminal acetyl group, so that a sequence-specific effect can be separated from a non-specific one. The cell-level assays that fit the product page's stated uses, scratch and transwell migration and endothelial tube formation, are covered in TB-500 angiogenesis and cell migration assays.

Stock preparation arithmetic

For any study the first number to fix is the stock concentration. The product page gives the relation as milligrams of peptide divided by milliliters of diluent: c = m / V. A 10 mg vial with 2 mL of diluent gives 5 mg/mL, and with 1 mL gives 10 mg/mL. For a published parameter expressed as a mass per animal, mass = reported amount per kg × body weight, and volume = mass / c. This is arithmetic for understanding how a published parameter relates to a stock, not a recommendation of any amount. The calculator runs the same steps, and the vial is stored at 2–8 °C short term and −20 °C long term, protected from light, with solutions kept cold and aliquoted (Manning and colleagues, 2010).

Verifying the material

A musculoskeletal study can run for months, so the identity of the test article at the start is worth documenting. The product page lists sequence confirmation among certificate contents where a certificate is published; match the lot number on the vial to the document on the COA page, and record the certificate in the study file. TB-500 purity testing explains the methods.

Limits of this article

The three cited animal studies use thymosin β4 protein, in single species, with specific carriers and schedules. None used TB-500 as the test article, and none reported on tendon in the strict sense: the ligament study is the nearest connective-tissue model. No conclusion about the fragment in muscle or tendon follows from them.

Related reading

Frequently asked questions

Are there studies of TB-500 itself in muscle or tendon?

The animal studies reviewed here used thymosin β4 protein. The TB-500 fragment appears in the literature in an analytical doping-control paper, not as a test article in these models.

What did the rat ligament study measure?

Histology by H&E, collagen fibril diameter by transmission electron microscopy, and biomechanical testing of the femur–ligament–tibia complex at 4 weeks after medial collateral ligament transection.

What was reported in the ligament study?

Exposed tissue had more uniform fiber bundles, larger collagen fibril diameters and higher mechanical properties than controls, with the protein delivered locally in a fibrin sealant.

What did the mdx mouse study report?

More regenerating skeletal muscle fibers in exposed mdx mice, but no significant improvement in grip strength, cardiac shortening fraction or fibrosis.

Why does endpoint class matter?

Histology describes tissue activity, while grip strength and echocardiography describe function. A study can move one class and not the other, and the two should not be merged in a summary.

Does a 4-week time point show durable repair?

No. One time point cannot show whether a difference persists, closes or reverses later.

Why does the route of administration matter?

Local delivery at a lesion in a carrier, topical use and chronic repeated administration answer different questions, so results cannot be carried between them.

Which control suits a carrier-delivered study?

A carrier-only arm, such as fibrin sealant without the protein, plus untreated animals where appropriate.

How do I convert a stock concentration to a per-animal volume?

Volume = (reported amount per kg × body weight) / stock concentration, with c = m / V for the stock. This is arithmetic, not a recommendation.

Is TB-500 from V8 for use in people or animals?

No. It is sold strictly for laboratory research use only.

Related reading: What Is TB-500? Decoding the Name, Sequence and Mass, TB-500 Research Questions, Answered With Sources, TB-500 Mechanism: When Thymosin β4 Knockouts Disagree.

References

  1. Xu B, Yang M, Li Z, et al. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013;184:1-5. doi:10.1016/j.regpep.2013.03.026
  2. Spurney CF, Cha HJ, Sali A, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010;5(1):e8976. doi:10.1371/journal.pone.0008976
  3. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
  4. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043
  5. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.